SCHEMBL4713736

SCHEMBL4713736

FC(F)(F)c1ccc(-c2nn(CC3CO3)cc2-c2ccncc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 8/20 0.51
SRC P12931 1/20 0.51
KDR P35968 1/20 0.51
KIF11 P52732 1/20 0.42
MAPK3 P27361 4/20 0.41
MAPK1 P28482 4/20 0.41
CSNK1D P48730 3/20 0.41
CSNK1E P49674 3/20 0.41
BMPR1B O00238 2/20 0.41
CIT O14578 2/20 0.41
RIPK2 O43353 2/20 0.41
STK10 O94804 2/20 0.41
MAP4K4 O95819 2/20 0.41
ABL1 P00519 2/20 0.41
RAF1 P04049 2/20 0.41
ERBB3 P21860 2/20 0.41
JAK1 P23458 2/20 0.41
ACVR1B P36896 2/20 0.41
TGFBR1 P36897 2/20 0.41
MAPK10 P53779 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716926 0.85 DRD2 (0.38) BRAFSRCKDRCSNK1DMAP4K4
SCHEMBL1645969 0.76 MAPK14 (0.49) BRAFSRCKDRCSNK1DCSNK1E
SCHEMBL16105552 0.75 CSNK1D (0.53) BRAFSRCKDRMAPK3MAPK1
SCHEMBL1647083 0.73 MAPK14 (0.57) BRAFSRCKDRMAPK3MAPK1
SCHEMBL5463467 0.72 MAPK13 (0.73) BRAFSRCKDRKIF11MAPK3
SCHEMBL1646015 0.69 MAPK14 (0.59) BRAFSRCKDRCSNK1DCSNK1E
SCHEMBL1648428 0.69 MAPK14 (0.55) BRAFSRCKDRMAPK3MAPK1
SCHEMBL1758859 0.69 PDE10A (0.58) BRAFSRCKDRMAPK3MAPK1
SCHEMBL28319828 0.69 CRHR1 (0.50) MAPK14MAPK13MAPK12MAPK11
SCHEMBL14839424 0.68 BRAF (1.00) BRAFSRCKDRKIF11CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1315490-B1 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARM INC (US) 2008-11-12 EP disclosed
US-20070117785-A1 Substituted pyrazoles and methods of treatment with substituted pyrazoles JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-24 US disclosed
EP-1309593-B1 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARM INC (US) 2006-03-15 EP disclosed
US-20050245576-A1 Substituted pyrazoles BUTLER CHRISTOPHER R 2005-11-03 US disclosed
US-6953793-B2 Substituted pyrazoles ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2005-10-11 US disclosed
US-20050101587-A9 Method for treating allergies using substituted pyrazoles ORTHO MCNEIL PHARMACEUTICALS, INC. 2005-05-12 US disclosed
US-6583155-B2 Administering 2-(1-(3-(5-Acetyl-3-(4-chloro-phenyl)-4,5,6,7-tetrahydro-pyrazolo-(4,3 -c)pyridin-1-yl)-2-hydroxy-propyl)-piperidin-4-ylamino)-benzonitrile for inhibiting cathepsins; for treating atopic diseases ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-06-24 US disclosed
EP-1315490-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES Ortho-McNeil Pharmaceutical, Inc. (US) 2003-06-04 EP disclosed
EP-1309593-A2 SUBSTITUTED PYRAZOLES Ortho-McNeil Pharmaceutical, Inc. (US) 2003-05-14 EP disclosed
US-20030078419-A1 Substituted pyrazoles ORTHO MCNEIL PHARMACEUTICAL, INC. 2003-04-24 US disclosed
US-20020115656-A1 Method for treating allergies using substituted pyrazoles BUTLER CHRISTOPHER R (US) 2002-08-22 US disclosed
US-20020055497-A1 Method for treating allergies using substituted pyrazoles BUTLER CHRISTOPHER R (US) 2002-05-09 US disclosed
WO-2002020011-A2 A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-03-14 WO disclosed
WO-2002014315-A2 SUBSTITUTED PYRAZOLES ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2002-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245576-A1 Substituted pyrazoles CTSS, CTSZ, CTSV BRAF 1513/4885SRC 2466/4885KDR 4728/4885
US-20030078419-A1 Substituted pyrazoles CTSS, CTSZ, CTSV BRAF 1513/4885SRC 2466/4885KDR 4728/4885
US-20020115656-A1 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 BRAF 2668/4885SRC 2129/4885KDR 3615/4885
US-20050101587-A9 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 BRAF 2668/4885SRC 2129/4885KDR 3615/4885
US-20020055497-A1 Method for treating allergies using substituted pyrazoles TSLP, IL33, HRH2 BRAF 2668/4885SRC 2129/4885KDR 3615/4885
US-20070117785-A1 Substituted pyrazoles and methods of treatment with substituted pyrazoles CTSS, CMA1, CTSZ BRAF 812/4885SRC 2253/4885KDR 4162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.